Leonard G. Gomella, MD, Thomas Jefferson University, Philadelphia, Pennsylvania, discusses whether Radium-223 should be used earlier in treating metastatic castration resistant prostate cancer.

Interview produced by Prostatepedia

Keywords: Radium-223, metastatic castration resistant prostate cancer

ABOUT THE AUTHOR

Bernard W. Godwin, Jr. Professor in Prostate Cancer at Thomas Jefferson University |  + posts

Leonard G. Gomella, MD, FACS, serves as the Bernard W. Godwin, Jr. Professor of Prostate Cancer, Chairman of the Department of Urology, Senior Director of Clinical Affairs for the Sidney Kimmel Comprehensive Cancer Center, and the Enterprise Vice President of Urology at the Jefferson Health System at Thomas Jefferson University in Philadelphia, Pennsylvania. Dr. Gomella's lab, a part of the Jefferson Sidney's Kimmel Comprehensive Cancer Center, is involved in clinical research for the development of techniques to treat cancers.